Literature DB >> 29478755

New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data.

Mohammadreza Shaghaghi1, Saeed Soleyman-Jahi2, Hassan Abolhassani3, Reza Yazdani4, Gholamreza Azizi5, Nima Rezaei6, Mohamed-Ridha Barbouche7, Mark A McKinlay8, Asghar Aghamohammadi9.   

Abstract

Widespread administration of oral poliovirus vaccine (OPV) has decreased global incidence of poliomyelitis by ≈99.9%. However, the emergence of vaccine-derived polioviruses (VDPVs) is threatening polio-eradication program. Primary immunodeficiency (PID) patients are at higher risks of vaccine-associated paralytic poliomyelitis (VAPP) and prolonged excretion of immunodeficiency-associated VDPV (iVDPV). We searched Embase, Medline, Science direct, Scopus, Web of Science, and CDC and WHO databases by 30 September 2016, for all reports of iVDPV cases. Patient-level data were extracted form eligible studies. Data on immunization coverage and income-level of countries were extracted from WHO/UNICEF and the WORLD BANK databases, respectively. We assessed bivariate associations between immunological, clinical, and virological parameters, and exploited multivariable modeling to identify independent determinants of poliovirus evolution and patients' outcomes. Study protocol was registered with PROSPERO (CRD42016052931). 4329 duplicate-removed titles were screened. A total of 107 iVDPV cases were identified from 68 eligible articles. The majority of cases were from higher income countries with high polio-immunization coverage. 74 (69.81%) patients developed VAPP. Combined immunodeficiency patients showed lower rates of VAPP (p < .001) and infection clearance (p = .02), compared to humoral immunodeficiency patients. The rate of poliovirus genomic evolution was higher at early stages of replication, decreasing over time until reaching a steady state. Independent of replication duration, higher extent (p = .04) and rates (p = .03) of genome divergence contributed to a less likelihood of virus clearance. PID type (p < .001), VAPP occurrence (p = .008), and income-level of country (p = .04) independently influenced patients' survival. With the use of OPV, new iVDPVs will emerge independent of the rate of immunization coverage. Inherent features of PIDs contribute to the clinical course of iVDPV infection and virus evolution. This finding could shed further light on poliomyelitis pathogenesis and iVDPV evolution pattern. It also has implications for public health, the polio eradication effort and the development of effective antiviral interventions.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Mutation; Oral poliovirus vaccine; Paralysis; Poliomyelitis; Primary immunodeficiency; Vaccine-derived poliovirus

Mesh:

Substances:

Year:  2018        PMID: 29478755     DOI: 10.1016/j.vaccine.2018.02.059

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

Review 1.  Clearing Vaccine-Derived Poliovirus Infection Following Hematopoietic Stem Cell Transplantation: a Case Report and Review of Literature.

Authors:  Mohammadreza Shaghaghi; Mona Irannejad; Hassan Abolhassani; Shohreh Shahmahmoodi; Amir Ali Hamidieh; Saeed Soleyman-Jahi; Reza Yazdani; Gholamreza Azizi; Asghar Aghamohammadi
Journal:  J Clin Immunol       Date:  2018-06-14       Impact factor: 8.317

Review 2.  Life-Threatening Infections Due to Live-Attenuated Vaccines: Early Manifestations of Inborn Errors of Immunity.

Authors:  Laura Pöyhönen; Jacinta Bustamante; Jean-Laurent Casanova; Emmanuelle Jouanguy; Qian Zhang
Journal:  J Clin Immunol       Date:  2019-05-23       Impact factor: 8.317

3.  Poliovirus-nonsusceptible Vero cell line for the World Health Organization global action plan.

Authors:  Yuko Okemoto-Nakamura; Kenji Someya; Toshiyuki Yamaji; Kyoko Saito; Makoto Takeda; Kentaro Hanada
Journal:  Sci Rep       Date:  2021-03-24       Impact factor: 4.379

Review 4.  Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.

Authors:  Radboud J Duintjer Tebbens; Kimberly M Thompson
Journal:  Expert Rev Vaccines       Date:  2018-08-09       Impact factor: 5.217

Review 5.  Biological Function and Application of Picornaviral 2B Protein: A New Target for Antiviral Drug Development.

Authors:  Zengbin Li; Zixiao Zou; Zeju Jiang; Xiaotian Huang; Qiong Liu
Journal:  Viruses       Date:  2019-06-04       Impact factor: 5.048

6.  Natural Clearance of Prolonged VDPV Infection in a Child With Primary Immunodeficiency Disorder.

Authors:  Madhu Chhanda Mohanty; Manisha Ranjan Madkaikar; Mukesh Desai; Jahnavi Aluri; Swapnil Yashwant Varose; Prasad Taur; Deepa Kailash Sharma; Uma Prajwal Nalavade; Sneha Vijay Rane; Maya Gupta; Snehal Shabarish; Aparna Dalvi; Jagadish Mohanrao Deshpande
Journal:  Front Immunol       Date:  2019-07-23       Impact factor: 7.561

7.  Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters.

Authors:  D A Kalkowska; M A Pallansch; K M Thompson
Journal:  Epidemiol Infect       Date:  2019-10-24       Impact factor: 2.451

8.  Poliovirus excretion following vaccination with live poliovirus vaccine in patients with primary immunodeficiency disorders: clinicians' perspectives in the endgame plan for polio eradication.

Authors:  Nermeen M Galal; Safaa Meshaal; Rabab ElHawary; Eman Nasr; Laila Bassiouni; Humayun Ashghar; Noha H Farag; Ondrej Mach; Cara Burns; Jane Iber; Qi Chen; Aisha ElMarsafy
Journal:  BMC Res Notes       Date:  2018-10-11

9.  Vaccine-Derived Poliovirus Infection among Patients with Primary Immunodeficiency and Effect of Patient Screening on Disease Outcomes, Iran.

Authors:  Mohammadreza Shaghaghi; Shohreh Shahmahmoodi; Ali Nili; Hassan Abolhassani; Seyedeh Panid Madani; Ahmad Nejati; Maryam Yousefi; Yaghoob M Kandelousi; Mona Irannejad; Shiva Shaghaghi; Seyed Mohsen Zahraei; Sussan Mahmoudi; Mohammad Mehdi Gouya; Reza Yazdani; Gholamreza Azizi; Nima Parvaneh; Asghar Aghamohammadi
Journal:  Emerg Infect Dis       Date:  2019-11       Impact factor: 6.883

10.  Causality assessment of adverse events following immunization: the problem of multifactorial pathology.

Authors:  Paolo Bellavite
Journal:  F1000Res       Date:  2020-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.